Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.67)
# 191
Out of 5,182 analysts
26
Total ratings
60.71%
Success rate
48.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $16 → $14 | $5.26 | +166.16% | 5 | Mar 23, 2026 | |
| CRVO CervoMed | Maintains: Buy | $19 → $11 | $3.82 | +187.96% | 5 | Mar 18, 2026 | |
| NRSN NeuroSense Therapeutics | Initiates: Buy | $3 | $0.75 | +299.73% | 1 | Mar 10, 2026 | |
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $2.69 | +11.52% | 1 | Dec 11, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.58 | +96.51% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $35.10 | -62.96% | 3 | Nov 12, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $140 → $60 | $0.88 | +6,691.17% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.90 | +233.33% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.95 | +207.69% | 3 | Aug 13, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $12.96 | +123.77% | 1 | Dec 5, 2024 |
Cingulate
Mar 23, 2026
Maintains: Buy
Price Target: $16 → $14
Current: $5.26
Upside: +166.16%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $19 → $11
Current: $3.82
Upside: +187.96%
NeuroSense Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $3
Current: $0.75
Upside: +299.73%
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $2.69
Upside: +11.52%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.58
Upside: +96.51%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $35.10
Upside: -62.96%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $140 → $60
Current: $0.88
Upside: +6,691.17%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.90
Upside: +233.33%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.95
Upside: +207.69%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $12.96
Upside: +123.77%